##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 154 No. 12 (2024)

Advancements in lung cancer: a comprehensive perspective on diagnosis, staging, therapy and follow-up from the SAKK Working Group on Imaging in Diagnosis and Therapy Monitoring

Cite this as:
Swiss Med Wkly. 2024;154:3843
Published
02.12.2024

Summary

In 2015, around 4400 individuals received a diagnosis of lung cancer, and Switzerland recorded approximately 3200 deaths related to lung cancer. Advances in detection, such as lung cancer screening and improved treatments, have led to increased identification of early-stage lung cancer and higher chances of long-term survival. This progress has introduced new considerations in imaging, emphasising non-invasive diagnosis and characterisation techniques like radiomics. Treatment aspects, such as preoperative assessment and the implementation of immune response evaluation criteria in solid tumours (iRECIST), have also seen advancements. For those undergoing curative treatment for lung cancer, guidelines propose follow-up with computed tomography (CT) scans within a specific timeframe. However, discrepancies exist in published guidelines, and there is a lack of universally accepted recommendations for follow-up procedures.

This white paper aims to provide a certain standard regarding the use of imaging on the diagnosis, staging, treatment and follow-up of patients with lung cancer.

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108. doi: https://doi.org/10.3322/caac.21262
  2. N. K. N. Bundesamt für Statistik (BFS). Kinderkrebsregister (KiKR), Schweizerischer Krebsbericht 2021, in Stand und Entwicklungen, Bundesamt für Statistik, Neuchatel, 2021. Available at: https://www.nkrs.ch/assets/files/publications/Krebsbericht2021/1177-2100-de.pdf
  3. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, et al.; National Lung Screening Trial Research Team. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013 Sep;369(10):920–31. doi: https://doi.org/10.1056/NEJMoa1208962
  4. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020 Feb;382(6):503–13. doi: https://doi.org/10.1056/NEJMoa1911793
  5. Park H, Sholl LM, Hatabu H, Awad MM, Nishino M. Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology. 2019 Oct;293(1):15–29. doi: https://doi.org/10.1148/radiol.2019190173
  6. Ko CC, Yeh LR, Kuo YT, Chen JH. Imaging biomarkers for evaluating tumor response: RECIST and beyond. Biomark Res. 2021 Jul;9(1):52. doi: https://doi.org/10.1186/s40364-021-00306-8
  7. Rubins J, Unger M, Colice GL; American College of Chest Physicians. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest. 2007 Sep;132(3 Suppl):355S–67S. doi: https://doi.org/10.1378/chest.07-1390
  8. Subramanian M, Liu J, Greenberg C, Schumacher J, Chang GJ, McMurry TL, et al. Imaging Surveillance for Surgically Resected Stage I Non-Small Cell Lung Cancer: Is More Always Better? J Thorac Cardiovasc Surg. 2019 Mar;157(3):1205–1217.e2. doi: https://doi.org/10.1016/j.jtcvs.2018.09.119
  9. Billè A, Ahmad U, Woo KM, Suzuki K, Adusumilli P, Huang J, et al. Detection of Recurrence Patterns After Wedge Resection for Early Stage Lung Cancer: Rationale for Radiologic Follow-Up. Ann Thorac Surg. 2016 Oct;102(4):1067–73. doi: https://doi.org/10.1016/j.athoracsur.2016.04.056
  10. Shah PK, Austin JH, White CS, Patel P, Haramati LB, Pearson GD, et al. Missed non-small cell lung cancer: radiographic findings of potentially resectable lesions evident only in retrospect. Radiology. 2003 Jan;226(1):235–41. doi: https://doi.org/10.1148/radiol.2261011924
  11. Quekel LG, Kessels AG, Goei R, van Engelshoven JM. Miss rate of lung cancer on the chest radiograph in clinical practice. Chest. 1999 Mar;115(3):720–4. doi: https://doi.org/10.1378/chest.115.3.720
  12. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al.; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug;365(5):395–409. doi: https://doi.org/10.1056/NEJMoa1102873
  13. Infante M, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G, et al.; DANTE Study Group. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009 Sep;180(5):445–53. doi: https://doi.org/10.1164/rccm.200901-0076OC
  14. Infante M, Sestini S, Galeone C, Marchianò A, Lutman FR, Angeli E, et al. Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials. Eur J Cancer Prev. 2017 Jul;26(4):324–9. doi: https://doi.org/10.1097/CEJ.0000000000000264
  15. MacMahon H, Naidich DP, Goo JM, Lee KS, Leung AN, Mayo JR, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017 Jul;284(1):228–43. doi: https://doi.org/10.1148/radiol.2017161659
  16. Rizzo S, Radice D, Femia M, De Marco P, Origgi D, Preda L, et al. Metastatic and non-metastatic lymph nodes: quantification and different distribution of iodine uptake assessed by dual-energy CT. Eur Radiol. 2018 Feb;28(2):760–9. doi: https://doi.org/10.1007/s00330-017-5015-5
  17. Somatostatin receptor physiology and targets for somatostatin analogue therapy. Abstracts of the Young Investigator Meeting. 31 October-2 November 2002, Barcelona, Spain, Eur J Endocrinol, vol. 148 Suppl 1, p. 50 pages, Jan 2003. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12602334
  18. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001 Feb;285(7):914–24. doi: https://doi.org/10.1001/jama.285.7.914
  19. Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM, Onko PE; Onko-PET der Deutschen Gesellschaft fur Nuklearmedizin. Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren. Diskussionsbasis der deutschen Konsensus-Konferenz Onko-PET 2000 - [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000]. Pneumologie. 2001 Aug;55(8):367–77. doi: https://doi.org/10.1055/s-2001-16201
  20. Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, et al.; Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst. 2007 Dec;99(23):1753–67. doi: https://doi.org/10.1093/jnci/djm232
  21. Fischer BM, Mortensen J, Højgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol. 2001 Nov;2(11):659–66. doi: https://doi.org/10.1016/S1470-2045(01)00555-1
  22. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer. 2004 Jul;45(1):19–27. doi: https://doi.org/10.1016/j.lungcan.2004.01.009
  23. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003 Jan;123(1 Suppl):137S–46S. doi: https://doi.org/10.1378/chest.123.1_suppl.137S
  24. Birim O, Kappetein AP, Stijnen T, Bogers AJ. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2005 Jan;79(1):375–82. doi: https://doi.org/10.1016/j.athoracsur.2004.06.041
  25. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA; American College of Chest Physicians. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):202S–20S. doi: https://doi.org/10.1378/chest.07-1362
  26. Hellwig D, Baum RP, Kirsch C. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin. 2009;48(2):59–69. doi: https://doi.org/10.3413/nukmed-0217
  27. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002 Apr;359(9315):1388–93. doi: https://doi.org/10.1016/S0140-6736(02)08352-6
  28. Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, et al.; POORT Study Group. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol. 2006 Apr;24(12):1800–6. doi: https://doi.org/10.1200/JCO.2005.02.4695
  29. Mayor S. NICE issues guidance for diagnosis and treatment of lung cancer. BMJ. 2005 Feb;330(7489):439. doi: https://doi.org/10.1136/bmj.330.7489.439-b
  30. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999 Sep;212(3):803–9. doi: https://doi.org/10.1148/radiology.212.3.r99se21803
  31. Fischer BM, Mortensen J, Langer SW, Loft A, Berthelsen AK, Petersen BI, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007 Feb;18(2):338–45. doi: https://doi.org/10.1093/annonc/mdl374
  32. Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004 Dec;31(12):1614–20. doi: https://doi.org/10.1007/s00259-004-1606-x
  33. Kut V, Spies W, Spies S, Gooding W, Argiris A. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol. 2007 Feb;30(1):45–50. doi: https://doi.org/10.1097/01.coc.0000239095.09662.19
  34. Niho S, Fujii H, Murakami K, Nagase S, Yoh K, Goto K, et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer. Lung Cancer. 2007 Sep;57(3):328–33. doi: https://doi.org/10.1016/j.lungcan.2007.04.001
  35. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004 Sep;5(9):531–40. doi: https://doi.org/10.1016/S1470-2045(04)01564-5
  36. Hellwig D, Gröschel A, Graeter TP, Hellwig AP, Nestle U, Schäfers HJ, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006 Jan;33(1):13–21. doi: https://doi.org/10.1007/s00259-005-1919-4
  37. Khaji RA, Kabwebwe VM, Mringo AG, Nkwabi TF, Bigio J, Mergenthaler C, et al. Factors Affecting Motivation among Key Populations to Engage with Tuberculosis Screening and Testing Services in Northwest Tanzania: A Mixed-Methods Analysis. Int J Environ Res Public Health. 2021 Sep;18(18):9654. doi: https://doi.org/10.3390/ijerph18189654
  38. Meier-Schroers M, Homsi R, Skowasch D, Buermann J, Zipfel M, Schild HH, et al. Lung cancer screening with MRI: results of the first screening round. J Cancer Res Clin Oncol. 2018 Jan;144(1):117–25. doi: https://doi.org/10.1007/s00432-017-2521-4
  39. Darçot E, Jreige M, Rotzinger DC, Gidoin Tuyet Van S, Casutt A, Delacoste J, et al. Comparison Between Magnetic Resonance Imaging and Computed Tomography in the Detection and Volumetric Assessment of Lung Nodules: A Prospective Study. Front Med (Lausanne). 2022 Apr;9:858731. doi: https://doi.org/10.3389/fmed.2022.858731
  40. Razek AA, Fathy A, Gawad TA. Correlation of apparent diffusion coefficient value with prognostic parameters of lung cancer. J Comput Assist Tomogr. 2011;35(2):248–52. doi: https://doi.org/10.1097/RCT.0b013e31820ccf73
  41. Chang YC, Yu CJ, Chen CM, Hu FC, Hsu HH, Tseng WY, et al. Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging. 2012 Aug;36(2):387–96. doi: https://doi.org/10.1002/jmri.23660
  42. Bandi V, Lunn W, Ernst A, Eberhardt R, Hoffmann H, Herth FJ. Ultrasound vs. CT in detecting chest wall invasion by tumor: a prospective study. Chest. 2008 Apr;133(4):881–6. doi: https://doi.org/10.1378/chest.07-1656
  43. Han Y, Kim HJ, Kong KA, Kim SJ, Lee SH, Ryu YJ, et al. Diagnosis of small pulmonary lesions by transbronchial lung biopsy with radial endobronchial ultrasound and virtual bronchoscopic navigation versus CT-guided transthoracic needle biopsy: A systematic review and meta-analysis. PLoS One. 2018 Jan;13(1):e0191590. doi: https://doi.org/10.1371/journal.pone.0191590
  44. Heerink WJ, de Bock GH, de Jonge GJ, Groen HJ, Vliegenthart R, Oudkerk M. Complication rates of CT-guided transthoracic lung biopsy: meta-analysis. Eur Radiol. 2017 Jan;27(1):138–48. doi: https://doi.org/10.1007/s00330-016-4357-8
  45. Wu CC, Maher MM, Shepard JA. Complications of CT-guided percutaneous needle biopsy of the chest: prevention and management. AJR Am J Roentgenol. 2011 Jun;196(6):W678-82. doi: https://doi.org/10.2214/AJR.10.4659
  46. Navani N, Fisher DJ, Tierney JF, Stephens RJ, Burdett S, Burdett S, et al.; NSCLC Meta-analysis Collaborative Group. The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data. Chest. 2019 Mar;155(3):502–9. doi: https://doi.org/10.1016/j.chest.2018.10.020
  47. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al.; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul;28 suppl_4:iv1–21. 10.1093/annonc/mdx222
  48. Donington J, Ferguson M, Mazzone P, Handy J Jr, Schuchert M, Fernando H, et al.; Thoracic Oncology Network of the American College of Chest Physicians and the Workforce on Evidence-Based Surgery of the Society of Thoracic Surgeons. American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. Chest. 2012 Dec;142(6):1620–35. doi: https://doi.org/10.1378/chest.12-0790
  49. Videtic GM, Chang JY, Chetty IJ, Ginsburg ME, Kestin LL, Kong FM, et al.; Expert Panel on Radiation OncologyLung. ACR appropriateness Criteria® early-stage non-small-cell lung cancer. Am J Clin Oncol. 2014 Apr;37(2):201–7. doi: https://doi.org/10.1097/COC.0000000000000013
  50. Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, et al.; ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi89–98. doi: https://doi.org/10.1093/annonc/mdt241
  51. Iguchi T, Hiraki T, Matsui Y, Mitsuhashi T, Katayama N, Katsui K, et al. Survival Outcomes of Treatment with Radiofrequency Ablation, Stereotactic Body Radiotherapy, or Sublobar Resection for Patients with Clinical Stage I Non-Small-Cell Lung Cancer: A Single-Center Evaluation. J Vasc Interv Radiol. 2020 Jul;31(7):1044–51. doi: https://doi.org/10.1016/j.jvir.2019.11.035
  52. Lam A, Yoshida EJ, Bui K, Fernando D, Nelson K, Abi-Jaoudeh N. A National Cancer Database Analysis of Radiofrequency Ablation versus Stereotactic Body Radiotherapy in Early-Stage Non-Small Cell Lung Cancer. J Vasc Interv Radiol. 2018 Sep;29(9):1211–1217.e1. doi: https://doi.org/10.1016/j.jvir.2018.04.029
  53. Bi N, Shedden K, Zheng X, Kong FS. Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. Int J Radiat Oncol Biol Phys. 2016 Aug;95(5):1378–90. doi: https://doi.org/10.1016/j.ijrobp.2016.04.016
  54. Uhlig J, Ludwig JM, Goldberg SB, Chiang A, Blasberg JD, Kim HS. Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database Study. Radiology. 2018 Dec;289(3):862–70. doi: https://doi.org/10.1148/radiol.2018180979
  55. Uhlig J, Mehta S, Case MD, Dhanasopon A, Blasberg J, Homer RJ, et al. Effectiveness of Thermal Ablation and Stereotactic Radiotherapy Based on Stage I Lung Cancer Histology. J Vasc Interv Radiol. 2021 Jul;32(7):1022–1028.e4. doi: https://doi.org/10.1016/j.jvir.2021.02.025
  56. S. J. Genshaft et al., Society of Interventional Radiology Quality Improvement Standards on Percutaneous Ablation of Non-Small Cell Lung Cancer and Metastatic Disease to the Lungs, J Vasc Interv Radiol, vol. 32, no. 8, pp. 1242 e1-1242 e10, Aug 2021.
  57. Venturini M, Cariati M, Marra P, Masala S, Pereira PL, Carrafiello G. CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours. Cardiovasc Intervent Radiol. 2020 May;43(5):667–83. doi: https://doi.org/10.1007/s00270-020-02432-6
  58. de Baère T, Palussière J, Aupérin A, Hakime A, Abdel-Rehim M, Kind M, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006 Aug;240(2):587–96. doi: https://doi.org/10.1148/radiol.2402050807
  59. Palussière J, Chomy F, Savina M, Deschamps F, Gaubert JY, Renault A, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial. J Cardiothorac Surg. 2018 Aug;13(1):91. doi: https://doi.org/10.1186/s13019-018-0773-y
  60. Abtin F, De Baere T, Dupuy DE, Genshaft S, Healey T, Khan S, et al. Updates on Current Role and Practice of Lung Ablation. J Thorac Imaging. 2019 Jul;34(4):266–77. doi: https://doi.org/10.1097/RTI.0000000000000417
  61. de Baère T, Woodrum D, Tselikas L, Abtin F, Littrup P, Deschamps F, et al. The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors With a 5-Year Follow-Up. J Thorac Oncol. 2021 Nov;16(11):1840–9. doi: https://doi.org/10.1016/j.jtho.2021.07.021
  62. Callstrom MR, Woodrum DA, Nichols FC, Palussiere J, Buy X, Suh RD, et al. Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE). J Thorac Oncol. 2020 Jul;15(7):1200–9. doi: https://doi.org/10.1016/j.jtho.2020.02.022
  63. Gahide G, Pavic M, Sirois C, Sirois M, Poon J, Grondin-Beaudoin B, et al. Outpatient Approach for the Treatment of Lung Tumors with Cryoablation under Moderate Sedation. J Vasc Interv Radiol. 2021 Dec;32(12):1701–3. doi: https://doi.org/10.1016/j.jvir.2021.09.003
  64. Kauczor HU, Baird AM, Blum TG, Bonomo L, Bostantzoglou C, Burghuber O, et al.; European Society of Radiology (ESR) and the European Respiratory Society (ERS). ESR/ERS statement paper on lung cancer screening. Eur Radiol. 2020 Jun;30(6):3277–94. doi: https://doi.org/10.1007/s00330-020-06727-7
  65. McKee BJ, McKee AB, Kitts AB, Regis SM, Wald C. Low-dose computed tomography screening for lung cancer in a clinical setting: essential elements of a screening program. J Thorac Imaging. 2015 Mar;30(2):115–29. doi: https://doi.org/10.1097/RTI.0000000000000139
  66. Mazzone P, Powell CA, Arenberg D, Bach P, Detterbeck F, Gould MK, et al. Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement. Chest. 2015 Feb;147(2):295–303. doi: https://doi.org/10.1378/chest.14-2500
  67. Kazerooni EA, Austin JH, Black WC, Dyer DS, Hazelton TR, Leung AN, et al.; American College of Radiology; Society of Thoracic Radiology. ACR-STR practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography (CT): 2014 (Resolution 4). J Thorac Imaging. 2014 Sep;29(5):310–6. doi: https://doi.org/10.1097/RTI.0000000000000097
  68. Eberth JM, Qiu R, Linder SK, Gallant NR, Munden RF. Computed tomography screening for lung cancer: a survey of society of thoracic radiology members. J Thorac Imaging. 2014 Sep;29(5):289–92. doi: https://doi.org/10.1097/RTI.0000000000000105
  69. Chelala L, Hossain R, Kazerooni EA, Christensen JD, Dyer DS, White CS. Lung-RADS Version 1.1: Challenges and a Look Ahead, From the AJR Special Series on Radiology Reporting and Data Systems. AJR Am J Roentgenol. 2021 Jun;216(6):1411–22. doi: https://doi.org/10.2214/AJR.20.24807
  70. Radiology AC. Lung CT Screening Reporting & Data System (Lung-RADS). Available at: https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/LungRADSAssessmentCategoriesv1-1.pdf
  71. Munden RF, Black WC, Hartman TE, MacMahon H, Ko JP, Dyer DS, et al. Managing Incidental Findings on Thoracic CT: Lung Findings. A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2021 Sep;18(9):1267–79. doi: https://doi.org/10.1016/j.jacr.2021.04.014
  72. Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, et al.; IASLC Pathology Committee. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2022 Dec;17(12):1335–54. doi: https://doi.org/10.1016/j.jtho.2022.09.109
  73. Petrella F, Rizzo S, Attili I, Passaro A, Zilli T, Martucci F, et al. Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options. Curr Oncol. 2023 Mar;30(3):3160–75. doi: https://doi.org/10.3390/curroncol30030239
  74. Neppl C, Keller MD, Scherz A, Dorn P, Schmid RA, Zlobec I, et al. Comparison of the 7th and 8th Edition of the UICC/AJCC TNM Staging System in Primary Resected Squamous Cell Carcinomas of the Lung-A Single Center Analysis of 354 Cases. Front Med (Lausanne). 2019 Sep;6:196. 10.3389/fmed.2019.00196
  75. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228–47. doi: https://doi.org/10.1016/j.ejca.2008.10.026
  76. Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, et al. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 2018 Nov;4(11):1543–52. doi: https://doi.org/10.1001/jamaoncol.2018.3676
  77. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al.; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143–52. doi: https://doi.org/10.1016/S1470-2045(17)30074-8
  78. Horeweg N, van Rosmalen J, Heuvelmans MA, van der Aalst CM, Vliegenthart R, Scholten ET, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol. 2014 Nov;15(12):1332–41. doi: https://doi.org/10.1016/S1470-2045(14)70389-4
  79. Larici AR, Farchione A, Franchi P, Ciliberto M, Cicchetti G, Calandriello L, et al. Lung nodules: size still matters. Eur Respir Rev. 2017 Dec;26(146):170025. doi: https://doi.org/10.1183/16000617.0025-2017
  80. Chen CY, Chen CH, Shen TC, Cheng WC, Hsu CN, Liao CH, et al. Lung cancer screening with low-dose computed tomography: experiences from a tertiary hospital in Taiwan. J Formos Med Assoc. 2016 Mar;115(3):163–70. doi: https://doi.org/10.1016/j.jfma.2015.11.007
  81. Heuvelmans MA, Vliegenthart R, de Koning HJ, Groen HJ, van Putten MJ, Yousaf-Khan U, et al. Quantification of growth patterns of screen-detected lung cancers: the NELSON study. Lung Cancer. 2017 Jun;108:48–54. doi: https://doi.org/10.1016/j.lungcan.2017.02.021
  82. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Tazelaar HD, et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology. 2007 Feb;242(2):555–62. doi: https://doi.org/10.1148/radiol.2422052090
  83. Christe A, Brönnimann A, Vock P. Volumetric analysis of lung nodules in computed tomography (CT): comparison of two different segmentation algorithm softwares and two different reconstruction filters on automated volume calculation. Acta Radiol. 2014 Feb;55(1):54–61. doi: https://doi.org/10.1177/0284185113492454
  84. National Lung Screening Trial Research Team. Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial. J Thorac Oncol. 2019 Oct;14(10):1732–42. doi: https://doi.org/10.1016/j.jtho.2019.05.044
  85. Pastorino U, Sverzellati N, Sestini S, Silva M, Sabia F, Boeri M, et al. Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening. Eur J Cancer. 2019 Sep;118:142–8. doi: https://doi.org/10.1016/j.ejca.2019.06.009
  86. Silva M, Milanese G, Sestini S, Sabia F, Jacobs C, van Ginneken B, et al. Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval. Eur Radiol. 2021 Apr;31(4):1956–68. doi: https://doi.org/10.1007/s00330-020-07275-w
  87. Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021 Mar;18(3):135–51. doi: https://doi.org/10.1038/s41571-020-00432-6
  88. Nishino M, Hatabu H, Sholl LM, Ramaiya NH. Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. Radiographics. 2017;37(5):1371–87. doi: https://doi.org/10.1148/rg.2017170015
  89. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2016 Feb;278(2):563–77. doi: https://doi.org/10.1148/radiol.2015151169
  90. Rizzo S, Petrella F, Buscarino V, De Maria F, Raimondi S, Barberis M, et al. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer. Eur Radiol. 2016 Jan;26(1):32–42. doi: https://doi.org/10.1007/s00330-015-3814-0
  91. de Jong EE, van Elmpt W, Rizzo S, Colarieti A, Spitaleri G, Leijenaar RT, et al. Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer. Lung Cancer. 2018 Oct;124:6–11. doi: https://doi.org/10.1016/j.lungcan.2018.07.023
  92. Botta F, Raimondi S, Rinaldi L, Bellerba F, Corso F, Bagnardi V, et al. Association of a CT-Based Clinical and Radiomics Score of Non-Small Cell Lung Cancer (NSCLC) with Lymph Node Status and Overall Survival. Cancers (Basel). 2020 May;12(6):1432. doi: https://doi.org/10.3390/cancers12061432
  93. Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017 Dec;7(12):1394–403. doi: https://doi.org/10.1158/2159-8290.CD-17-0716
  94. Nielsen LR, Stensgaard S, Meldgaard P, Sorensen BS. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach. Cancer Treat Res Commun. 2024;39:100802. doi: https://doi.org/10.1016/j.ctarc.2024.100802
  95. Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, et al.; HepNet Acute HCV IV Study Group. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017 Feb;17(2):215–22. doi: https://doi.org/10.1016/S1473-3099(16)30408-X
  96. Klang E. Deep learning and medical imaging. J Thorac Dis. 2018 Mar;10(3):1325–8. doi: https://doi.org/10.21037/jtd.2018.02.76
  97. Xu Y, Hosny A, Zeleznik R, Parmar C, Coroller T, Franco I, et al. Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging. Clin Cancer Res. 2019 Jun;25(11):3266–75. doi: https://doi.org/10.1158/1078-0432.CCR-18-2495
  98. Sesen MB, Nicholson AE, Banares-Alcantara R, Kadir T, Brady M. Bayesian networks for clinical decision support in lung cancer care. PLoS One. 2013 Dec;8(12):e82349. doi: https://doi.org/10.1371/journal.pone.0082349
  99. Cunliffe A, Armato SG 3rd, Castillo R, Pham N, Guerrero T, Al-Hallaq HA. Lung texture in serial thoracic computed tomography scans: correlation of radiomics-based features with radiation therapy dose and radiation pneumonitis development. Int J Radiat Oncol Biol Phys. 2015 Apr;91(5):1048–56. doi: https://doi.org/10.1016/j.ijrobp.2014.11.030
  100. Krafft SP, Rao A, Stingo F, Briere TM, Court LE, Liao Z, et al. Erratum: “The utility of quantitative CT radiomics features for improved prediction of radiation pneumonitis” [Med. Phys. Vol. 45(11):5317-5324 (2018)] [Med. Phys. Vol. 45(11):5317-5324 (2018)]. Med Phys. 2019 Feb;46(2):1079. 10.1002/mp.13327
  101. Traverso A, Wee L, Dekker A, Gillies R. Repeatability and Reproducibility of Radiomic Features: A Systematic Review. Int J Radiat Oncol Biol Phys. 2018 Nov;102(4):1143–58. doi: https://doi.org/10.1016/j.ijrobp.2018.05.053
  102. Zwanenburg A, Vallières M, Abdalah MA, Aerts HJ, Andrearczyk V, Apte A, et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology. 2020 May;295(2):328–38. doi: https://doi.org/10.1148/radiol.2020191145
  103. Ligero M, Jordi-Ollero O, Bernatowicz K, Garcia-Ruiz A, Delgado-Muñoz E, Leiva D, et al. Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. Eur Radiol. 2021 Mar;31(3):1460–70. doi: https://doi.org/10.1007/s00330-020-07174-0
  104. Setio AA, Traverso A, de Bel T, Berens MS, Bogaard CV, Cerello P, et al. Validation, comparison, and combination of algorithms for automatic detection of pulmonary nodules in computed tomography images: the LUNA16 challenge. Med Image Anal. 2017 Dec;42:1–13. doi: https://doi.org/10.1016/j.media.2017.06.015
  105. Liang M, Tang W, Xu DM, Jirapatnakul AC, Reeves AP, Henschke CI, et al. Low-Dose CT Screening for Lung Cancer: Computer-aided Detection of Missed Lung Cancers. Radiology. 2016 Oct;281(1):279–88. doi: https://doi.org/10.1148/radiol.2016150063
  106. Grossmann P, Stringfield O, El-Hachem N, Bui MM, Rios Velazquez E, Parmar C, et al. Defining the biological basis of radiomic phenotypes in lung cancer. eLife. 2017 Jul;6:e23421. doi: https://doi.org/10.7554/eLife.23421
  107. Wu G, Jochems A, Refaee T, Ibrahim A, Yan C, Sanduleanu S, et al. Structural and functional radiomics for lung cancer. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3961–74. doi: https://doi.org/10.1007/s00259-021-05242-1
  108. Balagurunathan Y, Beers A, Mcnitt-Gray M, Hadjiiski L, Napel S, Goldgof D, et al. Lung Nodule Malignancy Prediction in Sequential CT Scans: summary of ISBI 2018 Challenge. IEEE Trans Med Imaging. 2021 Dec;40(12):3748–61. doi: https://doi.org/10.1109/TMI.2021.3097665
  109. Xiao N, Qiang Y, Zia MB, Wang S, Lian J. Ensemble classification for predicting the malignancy level of pulmonary nodules on chest computed tomography images. Oncol Lett. 2020 Jul;20(1):401–8. doi: https://doi.org/10.3892/ol.2020.11576
  110. Liu S, Liu S, Zhang C, Yu H, Liu X, Hu Y, et al. Exploratory Study of a CT Radiomics Model for the Classification of Small Cell Lung Cancer and Non-small-Cell Lung Cancer. Front Oncol. 2020 Sep;10:1268. doi: https://doi.org/10.3389/fonc.2020.01268
  111. Zhu X, Dong D, Chen Z, Fang M, Zhang L, Song J, et al. Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer. Eur Radiol. 2018 Jul;28(7):2772–8. doi: https://doi.org/10.1007/s00330-017-5221-1
  112. Song L, Zhu Z, Mao L, Li X, Han W, Du H, et al. Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients. Front Oncol. 2020 Mar;10:369. doi: https://doi.org/10.3389/fonc.2020.00369
  113. Gaga M, Powell CA, Schraufnagel DE, Schönfeld N, Rabe K, Hill NS, et al.; ATS/ERS Task Force on the Role of the Pulmonologist in the Management of Lung Cancer. An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med. 2013 Aug;188(4):503–7. doi: https://doi.org/10.1164/rccm.201307-1269ST
  114. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021 Aug;398(10299):535–54. doi: https://doi.org/10.1016/S0140-6736(21)00312-3
  115. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e211S–50S. doi: https://doi.org/10.1378/chest.12-2355
  116. Vilmann P, Frost Clementsen P, Colella S, Siemsen M, De Leyn P, Dumonceau JM, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg. 2015 Jul;48(1):1–15. doi: https://doi.org/10.1093/ejcts/ezv194
  117. Navani N, Butler R, Ibrahimo S, Verma A, Evans M, Doherty GJ, et al. Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement. Lung Cancer. 2022 Oct;172:142–53. doi: https://doi.org/10.1016/j.lungcan.2022.08.003
  118. Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, et al.; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015 Dec;10(12):1675–84. doi: https://doi.org/10.1097/JTO.0000000000000678
  119. Eberhardt WE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A 3rd, et al.; International Association for Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015 Nov;10(11):1515–22. doi: https://doi.org/10.1097/JTO.0000000000000673
  120. Yang L, Wang S, Zhou Y, Lai S, Xiao G, Gazdar A, et al. Evaluation of the 7th and 8th editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort. Oncotarget. 2017 May;8(40):66784–95. doi: https://doi.org/10.18632/oncotarget.18158
  121. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW; American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):243S–65S. 10.1378/chest.07-1379
  122. De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014 May;45(5):787–98. doi: https://doi.org/10.1093/ejcts/ezu028
  123. Turna A, Melek H, Kara HV, Kılıç B, Erşen E, Kaynak K. Validity of the updated European Society of Thoracic Surgeons staging guideline in lung cancer patients. J Thorac Cardiovasc Surg. 2018 Feb;155(2):789–95. doi: https://doi.org/10.1016/j.jtcvs.2017.09.090
  124. Travis WD. Pathology of lung cancer. Clin Chest Med. 2011 Dec;32(4):669–92. doi: https://doi.org/10.1016/j.ccm.2011.08.005
  125. Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, et al.; European Respiratory Society; European Society of Thoracic Surgeons Joint Task Force on Fitness For Radical Therapy. The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. Eur J Cardiothorac Surg. 2009 Jul;36(1):181–4. doi: https://doi.org/10.1016/j.ejcts.2009.04.022
  126. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw. 2023 Apr;21(4):340–50. doi: https://doi.org/10.6004/jnccn.2023.0020
  127. Ezer N, Kale M, Sigel K, Lakha S, Mhango G, Goodman E, et al. Outcomes after Video-assisted Thoracoscopic Lobectomy versus Open Lobectomy for Early-Stage Lung Cancer in Older Adults. Ann Am Thorac Soc. 2018 Jan;15(1):76–82. doi: https://doi.org/10.1513/AnnalsATS.201612-980OC
  128. Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al.; West Japan Oncology Group and Japan Clinical Oncology Group. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022 Apr;399(10335):1607–17. doi: https://doi.org/10.1016/S0140-6736(21)02333-3
  129. Zhu L, Wang T, Wu J, Zhai X, Wu Q, Deng H, et al. [Updated Interpretation of the NCCN Clinical Practice Guidelines (Version 3. 2023) for Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2023 Jun;26(6):407–15.